Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16).

Publication

Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16).

Journal Paper/Review - Feb 8, 2023

Gillessen Silke, Procopio Giuseppe, Hayoz Stefanie, Kremer Eloïse, Schwitter Michael, Caffo Orazio, Lorente David, Pedrazzini Augusto, Roubaud Guilhem, Nenan Soazig, Omlin Aurelius, Buttigliero Consuelo, Delgado Mingorance Juan Ignacio, González-Del-Alba Aránzazu, Delgado Maria Teresa, Nolè Franco, Turco Fabio, Mestre Ricardo Pereira, Ribi Karin, Cathomas Richard

Citation

Gillessen S, Procopio G, Hayoz S, Kremer E, Schwitter M, Caffo O, Lorente D, Pedrazzini A, Roubaud G, Nenan S, Omlin A, Buttigliero C, Delgado Mingorance J, González-Del-Alba A, Delgado M, Nolè F, Turco F, Mestre R, Ribi K, Cathomas R. Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16). J Clin Oncol 2023; 41:3608-3615.

Type

Journal Paper/Review (English)

Journal

J Clin Oncol 2023; 41

Publication Date

Feb 8, 2023

Issn Electronic

1527-7755

Pages

3608-3615

Brief description/objective

To assess the efficacy and safety of darolutamide maintenance after successful taxane chemotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC).